These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

602 related items for PubMed ID: 26631238

  • 1. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT.
    Maina T, Bergsma H, Kulkarni HR, Mueller D, Charalambidis D, Krenning EP, Nock BA, de Jong M, Baum RP.
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):964-973. PubMed ID: 26631238
    [Abstract] [Full Text] [Related]

  • 2. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
    Nock BA, Kaloudi A, Lymperis E, Giarika A, Kulkarni HR, Klette I, Singh A, Krenning EP, de Jong M, Maina T, Baum RP.
    J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272
    [Abstract] [Full Text] [Related]

  • 3. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
    Chatalic KL, Franssen GM, van Weerden WM, McBride WJ, Laverman P, de Blois E, Hajjaj B, Brunel L, Goldenberg DM, Fehrentz JA, Martinez J, Boerman OC, de Jong M.
    J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139
    [Abstract] [Full Text] [Related]

  • 4. Radiometal-Dependent Biological Profile of the Radiolabeled Gastrin-Releasing Peptide Receptor Antagonist SB3 in Cancer Theranostics: Metabolic and Biodistribution Patterns Defined by Neprilysin.
    Lymperis E, Kaloudi A, Sallegger W, Bakker IL, Krenning EP, de Jong M, Maina T, Nock BA.
    Bioconjug Chem; 2018 May 16; 29(5):1774-1784. PubMed ID: 29664606
    [Abstract] [Full Text] [Related]

  • 5. Synthesis and Evaluation of the First 68Ga-Labeled C-Terminal Hydroxamate-Derived Gastrin-Releasing Peptide Receptor-Targeted Tracers for Cancer Imaging with Positron Emission Tomography.
    Wang L, Kuo HT, Chen CC, Chapple D, Colpo N, Ng P, Lau WS, Jozi S, Bénard F, Lin KS.
    Molecules; 2024 Jun 28; 29(13):. PubMed ID: 38999054
    [Abstract] [Full Text] [Related]

  • 6. GRPr Antagonist 68Ga-SB3 PET/CT Imaging of Primary Prostate Cancer in Therapy-Naïve Patients.
    Bakker IL, Fröberg AC, Busstra MB, Verzijlbergen JF, Konijnenberg M, van Leenders GJLH, Schoots IG, de Blois E, van Weerden WM, Dalm SU, Maina T, Nock BA, de Jong M.
    J Nucl Med; 2021 Nov 28; 62(11):1517-1523. PubMed ID: 33789933
    [Abstract] [Full Text] [Related]

  • 7. A comparative PET imaging study of 44gSc- and 68Ga-labeled bombesin antagonist BBN2 derivatives in breast and prostate cancer models.
    Ferguson S, Wuest M, Richter S, Bergman C, Dufour J, Krys D, Simone J, Jans HS, Riauka T, Wuest F.
    Nucl Med Biol; 2020 Nov 28; 90-91():74-83. PubMed ID: 33189947
    [Abstract] [Full Text] [Related]

  • 8. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
    Zhang H, Desai P, Koike Y, Houghton J, Carlin S, Tandon N, Touijer K, Weber WA.
    J Nucl Med; 2017 Jan 28; 58(1):29-35. PubMed ID: 27516447
    [Abstract] [Full Text] [Related]

  • 9. 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology.
    Dalm SU, Bakker IL, de Blois E, Doeswijk GN, Konijnenberg MW, Orlandi F, Barbato D, Tedesco M, Maina T, Nock BA, de Jong M.
    J Nucl Med; 2017 Feb 28; 58(2):293-299. PubMed ID: 27609789
    [Abstract] [Full Text] [Related]

  • 10. Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts.
    Schroeder RP, van Weerden WM, Krenning EP, Bangma CH, Berndsen S, Grievink-de Ligt CH, Groen HC, Reneman S, de Blois E, Breeman WA, de Jong M.
    Eur J Nucl Med Mol Imaging; 2011 Jul 28; 38(7):1257-66. PubMed ID: 21431398
    [Abstract] [Full Text] [Related]

  • 11. In Vivo Stabilized SB3, an Attractive GRPR Antagonist, for Pre- and Intra-Operative Imaging for Prostate Cancer.
    Bakker IL, van Tiel ST, Haeck J, Doeswijk GN, de Blois E, Segbers M, Maina T, Nock BA, de Jong M, Dalm SU.
    Mol Imaging Biol; 2018 Dec 28; 20(6):973-983. PubMed ID: 29556947
    [Abstract] [Full Text] [Related]

  • 12. A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging.
    Pan D, Xu YP, Yang RH, Wang L, Chen F, Luo S, Yang M, Yan Y.
    Amino Acids; 2014 Jun 28; 46(6):1481-9. PubMed ID: 24633452
    [Abstract] [Full Text] [Related]

  • 13. [99mTc]Tc-DB1 Mimics with Different-Length PEG Spacers: Preclinical Comparison in GRPR-Positive Models.
    Kanellopoulos P, Lymperis E, Kaloudi A, de Jong M, Krenning EP, Nock BA, Maina T.
    Molecules; 2020 Jul 28; 25(15):. PubMed ID: 32731473
    [Abstract] [Full Text] [Related]

  • 14. Clinical Translation of a Dual Integrin αvβ3- and Gastrin-Releasing Peptide Receptor-Targeting PET Radiotracer, 68Ga-BBN-RGD.
    Zhang J, Niu G, Lang L, Li F, Fan X, Yan X, Yao S, Yan W, Huo L, Chen L, Li Z, Zhu Z, Chen X.
    J Nucl Med; 2017 Feb 28; 58(2):228-234. PubMed ID: 27493267
    [Abstract] [Full Text] [Related]

  • 15. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
    Chen X, Park R, Hou Y, Tohme M, Shahinian AH, Bading JR, Conti PS.
    J Nucl Med; 2004 Aug 28; 45(8):1390-7. PubMed ID: 15299066
    [Abstract] [Full Text] [Related]

  • 16. New Gastrin Releasing Peptide Receptor-Directed [99mTc]Demobesin 1 Mimics: Synthesis and Comparative Evaluation.
    Nock BA, Charalambidis D, Sallegger W, Waser B, Mansi R, Nicolas GP, Ketani E, Nikolopoulou A, Fani M, Reubi JC, Maina T.
    J Med Chem; 2018 Apr 12; 61(7):3138-3150. PubMed ID: 29517903
    [Abstract] [Full Text] [Related]

  • 17. Synthesis, preclinical, and initial clinical evaluation of integrin αVβ3 and gastrin-releasing peptide receptor (GRPR) dual-targeting radiotracer [68Ga]Ga-RGD-RM26-03.
    Wen X, Wang R, Xu P, Shi M, Shang Q, Zeng X, Zeng X, Liu J, Wang X, Zhu Z, Guo Z, Chen X, Zhang J.
    Eur J Nucl Med Mol Imaging; 2024 Jun 12; 51(7):2023-2035. PubMed ID: 38376806
    [Abstract] [Full Text] [Related]

  • 18. Radiometal Complexes as Pharmacokinetic Modifiers: A Potent 68Ga-Labeled Gastrin-Releasing Peptide Receptor Antagonist Based on the Macrocyclic Metal Chelator NODIA-Me.
    Schreck MV, Burgard C, Schmidtke A, Hierlmeier I, Stemler T, Maus S, Rosar F, Jung M, Speicher A, Ezziddin S, Holland JP, Bartholomä MD.
    Mol Pharm; 2023 Dec 04; 20(12):6463-6473. PubMed ID: 37978936
    [Abstract] [Full Text] [Related]

  • 19. 64Cu-NO2A-RGD-Glu-6-Ahx-BBN(7-14)NH2: a heterodimeric targeting vector for positron emission tomography imaging of prostate cancer.
    Jackson AB, Nanda PK, Rold TL, Sieckman GL, Szczodroski AF, Hoffman TJ, Chen X, Smith CJ.
    Nucl Med Biol; 2012 Apr 04; 39(3):377-87. PubMed ID: 22226021
    [Abstract] [Full Text] [Related]

  • 20. PET Using a GRPR Antagonist 68Ga-RM26 in Healthy Volunteers and Prostate Cancer Patients.
    Zhang J, Niu G, Fan X, Lang L, Hou G, Chen L, Wu H, Zhu Z, Li F, Chen X.
    J Nucl Med; 2018 Jun 04; 59(6):922-928. PubMed ID: 29123014
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.